MARKET WIREYahoo Finance • 17h ago
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusYahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
Why ABCL Stock dropped -6.19% Today — RQD Quant Desk Flash
$12.27 -6.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.11
AbCellera Biologics Inc. (ABCL) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $3.97B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ABCL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, AbCellera Biologics Inc. (NASDAQ: ABCL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $12.27 (-6.19% 1D, market cap $3.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABCL ranks #381 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ABCL compare to ARQT and LQDA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABCL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.5%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and LQDA (Liquidia Corporation) posts a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ABCL?
▼
Per ABCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703057), AbCellera Biologics Inc. generated $75.1M in revenue (+160.6% YoY), -$146.4M in net income, and -$174.1M in free cash flow against $1.36B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.11 (-1.30%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABCL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY ABCL SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)
Altman Z-Score 6.60 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$12.64-5.6% Next Q
52
Q2 (-2Q)Grade D$11.93+1.3% Next Q
49
Q3 (-1Q)Grade D$12.08+1.6% Next Q
47
CurrentGrade D$12.27-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABCL Turnaround Squeeze
While ABCL currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.31) and Max Pain ($12.88) forces dealer call-delta covering toward $15.77.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABCL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABCL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABCL Stock dropped -6.19% Today — RQD Quant Desk Flash
AbCellera Biologics Inc. (ABCL) dropped -6.19% to $12.27, trading at 78% of its 52-week range ($2.74 – $15.02). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 78% of its 52-week range ($2.74 – $15.02) with RSI-14 at 49 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $12.27 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ABCL Headlines & Catalysts
MARKET WIREwww.marketscreener.com • 20h ago
Certain Common Stock of AbCellera Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.www.marketscreener.com report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 23h ago
UBS Initiates AbCellera Biologics at Buy With $18 Price TargetYahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Is AbCellera Biologics (ABCL) Undervalued On Positive Phase 2 ABCL635 Results?Simply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
AbCellera Biologics (ABCL) Institutional Ownership 2026MarketBeat report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
AbCellera Biologics (NasdaqGS:ABCL) Stock Forecast & Analyst PredictionsSimply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.siam.in/ • 1d ago
AbCellera (ABCL) Sinks -6.94% as Volume Spikes on Downside 2026-10-17 - Demand Zonehttps://www.siam.in/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
AbCellera Biologics (ABCL) Shares Advance 4.37% to $12.54, Nearing Upper Range - Institutional Sentimenthttps://www.dars.gov.et/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 11d ago
AbCellera to Present at Upcoming Investor Conferences in November 2026VANCOUVER, British Columbia, October 22, 2026--AbCellera to Present at Upcoming Investor Conferences in November 2026
MARKET WIREYahoo • 21d ago
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABCL)
- ✓Walkthrough of ABCL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABCL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +167.32%🛡️ HOLDING TREND SUPPORT
2026-11-03O $13.08H $13.08L $12.27C $12.27VOL 3.88M
RES: $17.22SUP: $11.67SMA50: $12.31SMA200: $6.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABCL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +160.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ABCL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABCL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABCL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABCL)
Health Care Rank #381 of 1016
⚔️ ARQT vs ABCL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABCL vs. ARQT, LQDA, TNGX, INDV)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, AbCellera Biologics Inc. (ABCL) ranks #381 by composite RQD confidence (44/100, grade D) and #183 by equity capitalization ($3.97B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. ARQT currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ABCL at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABCL
ACTIVE
AbCellera Biologics Inc. | D | 44/100 | — | — | -20.5% | -6.19% | $3.97B | Benchmark Subject |
| ARQT Arcutis Biotherapeutics Inc. | D+ | 54/100 | — | 90.2% | -3.0% | +0.31% | $4.03B | /arqt-vs-abcl → |
| LQDA Liquidia Corporation | D- | 36/100 | — | — | -12.6% | +0.16% | $4.03B | /lqda-vs-abcl → |
| TNGX Tango Therapeutics Inc. | D | 45/100 | — | — | -28.9% | +0.84% | $3.83B | /tngx-vs-abcl → |
| INDV Indivior Pharmaceuticals Inc. | D | 51/100 | 19.8x | 80.2% | 62.2% | +0.34% | $4.17B | /indv-vs-abcl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001703057In its most recent audited fiscal period (FY2025, filed 2025-12-31), AbCellera Biologics Inc. (ABCL) reported GAAP revenue of $75.1M (+160.6% vs. FY2024 revenue of $28.8M , and +97.6% cumulative change since FY2023) , GAAP net income of -$146.4M, operating cash flow of -$131.3M, and free cash flow of -$174.1M (+6.9% YoY). On the balance sheet, ABCL closed FY2025 with $1.36B in total assets against $0 in total debt (Altman Z-Score: 6.60, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $75.1M | -$146.4M | -$131.3M | -$174.1M | $1.36B | — |
| FY2024 (FY) | 2024-12-31 | $28.8M | -$162.9M | -$108.6M | -$187.0M | $1.36B | — |
| FY2023 (FY) | 2023-12-31 | $38.0M | -$146.4M | -$43.9M | -$43.9M | — | — |
3. ABCL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, AbCellera Biologics Inc. (NASDAQ: ABCL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $12.27 (-6.19% 1D, market cap $3.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABCL ranks #381 in composite RQD confidence.
How does ABCL compare to ARQT and LQDA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABCL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.5%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and LQDA (Liquidia Corporation) posts a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABCL?
Per ABCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703057), AbCellera Biologics Inc. generated $75.1M in revenue (+160.6% YoY), -$146.4M in net income, and -$174.1M in free cash flow against $1.36B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABCL trading relative to its 50-day, 200-day, and 52-week technical levels?
ABCL last traded at $12.27 (-6.19% on volume of 3,876,717 shares), positioning the stock -0.32% below its 50-day simple moving average ($12.31) and +78.08% above its 200-day simple moving average ($6.89). Across its 52-week range of $2.74 to $15.02, ABCL sits at the 77.6% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.74 to $13.80).
ABCL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ABCL stock moving today?
Why ABCL Stock dropped -6.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 44/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ABCL — AbCellera Biologics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:00Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ABCL scores 38 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental cash engine (8/20): Per the RQD rating, ROIC is -20.5% and FCF yield is -4.11%. Per the SEC financials, FY 2025 free cash flow was $-174.1M against revenue of $75.1M. For a prospective investor, this pillar signals that the business is consuming cash rather than generating it, so valuation depends on future cash generation that the source data does not demonstrate.
- Whale / 13F flow (7/20): The RQD rating assigns 7/20 to institutional accumulation and options positioning. No 13F holder detail is included in the source data, so the drivers behind this score cannot be verified here. Institutional support, where it exists, is a relevant offset to weak fundamentals but is not confirmed by the holder data provided.
- Insider conviction (3/20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is weak. The holders section contains no insider transactions, so the low score is noted but not decomposed. A prospective investor should read this as an absence of visible insider buying support.
- Macro regime fit (6/20): Per the RQD rating, beta is 1.0 and sector sensitivity is a drag. Beta of 1.0 means the stock is expected to move in line with the market, offering no defensive cushion in risk-off environments.
- Forensic balance sheet (14/20): Per the RQD rating, Altman Z is 6.6, Piotroski F is 4/9, and Debt/Equity is 0.5. This is the strongest pillar. A high Altman Z suggests low near-term bankruptcy risk, while a Piotroski F of 4/9 indicates mixed rather than strong financial health. Cash of $128.5M at FY 2025 (per the SEC financials) provides a runway reference, though burn at the reported FCF rate means this cushion is finite.
Investor implications: The primary upside driver is the news flow around the ABCL635 program (see Recent Catalysts). Valuation tradeoffs are severe: at a $4.24B market cap with negative operating margin of -60% and negative ROIC, the equity price is pricing in future execution the reported financials do not yet show. The RQD score reflects that the balance sheet is not the primary risk; the cash-burn rate and weak flow signals are.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $75.1M | $-217.1M | $-146.4M | N/A | $-174.1M | $128.5M | N/A |
| FY 2024 | $28.8M | $-314.8M | $-162.9M | N/A | $-187.0M | $156.3M | N/A |
| FY 2023 | $38.0M | $-237.2M | $-146.4M | N/A | $-43.9M | N/A | N/A |
Per the SEC financials, revenue rose from $28.8M in FY 2024 to $75.1M in FY 2025 while operating losses narrowed from $-314.8M to $-217.1M. Net margin is -60% and operating margin is -60% per the market data. ROIC is -20.5% and the RQD rating cites an Altman Z-Score of 6.6 and a Piotroski F-Score of 4/9. Debt/Equity is 0.5 per the RQD rating; reported cash declined from $156.3M to $128.5M over FY 2025.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the key items are:
- Positive clinical read-through: Coverage of ABCL635 data and a Simply Wall St piece describing "positive Phase 2 ABCL635 results" (both flagged YELLOW, MARKET WIRE).
- Valuation framing: A Yahoo Finance piece suggesting the stock "could be 27% undervalued" as ABCL635 data draws focus.
- Analyst initiation: A report that UBS initiated coverage at Buy with an $18 price target.
- Risk watch item: A MarketScreener notice that certain common stock is subject to a lock-up agreement ending 13-OCT-2026, a potential supply overhang.
- Ownership coverage: A MarketBeat institutional ownership item for 2026.
Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals. Catalyst relevance is therefore limited to the news items above.
Open Questions
- What are the reported P/E, EPS, and EV/EBITDA values, which are missing from the source data and prevent a valuation-multiple comparison?
- What is the company's revenue composition and customer base, since the source data gives only aggregate revenue?
- What is the debt balance, given FY 2025 debt is N/A while Debt/Equity is reported as 0.5?
- What is the size and timing of the lock-up expiry on 13-OCT-2026, and how many shares does it affect?
- What do institutional 13F filings show about accumulation or reduction, since the holders data is empty?
ABCL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for AbCellera Biologics Inc. (ABCL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 17h ago
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus Yahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 20h ago
Certain Common Stock of AbCellera Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026. www.marketscreener.com report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 23h ago
UBS Initiates AbCellera Biologics at Buy With $18 Price Target Yahoo Finance report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Is AbCellera Biologics (ABCL) Undervalued On Positive Phase 2 ABCL635 Results? Simply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
AbCellera Biologics (ABCL) Institutional Ownership 2026 MarketBeat report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
AbCellera Biologics (NasdaqGS:ABCL) Stock Forecast & Analyst Predictions Simply Wall St report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.siam.in/ • 1d ago
AbCellera (ABCL) Sinks -6.94% as Volume Spikes on Downside 2026-10-17 - Demand Zone https://www.siam.in/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
AbCellera Biologics (ABCL) Shares Advance 4.37% to $12.54, Nearing Upper Range - Institutional Sentiment https://www.dars.gov.et/ report covering AbCellera Biologics Inc. (ABCL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ABCL Bull vs. Bear Conversation Board — What's Your Call at $12.27?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABCL 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $10.80 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ABCL (D- • RQD 38/100) a Buy at $12.27?
Welcome to the ABCL (AbCellera Biologics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $9.82 (-20.0%)
Spot @ $12.27 Pump the brakes on ABCL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ABCL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless AbCellera Biologics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $15.09 (+23.0%)
Spot @ $12.27 ABCL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ABCL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.27 (52-wk range $2.75 - $15.02), any beat on forward guidance forces shorts and underweight funds to chase.